In August, Zongertinib received FDA approval for previously treated HER2-mutant NSCLC. It now shows efficacy in first-line treatment, with a 77% objective response rate and 96% disease control rate.

Please provide your email address to receive an email when new articles are posted on . Immune checkpoint inhibitor-based combinations are the preferred first-line therapy for metastatic clear cell ...

NCCN upgrades Trodelvy to category 1 preferred first-line therapy for metastatic TNBC with CPS <10 and no germline BRCA1/2 mutation. For PD-L1–positive metastatic TNBC (CPS ≥10), Trodelvy plus ...

Enhertu plus Perjeta received FDA priority review for first-line treatment of HER2-positive metastatic breast cancer, showing significant improvements in progression-free survival and response rates.

Understanding the patterns of acquired resistance to epidermal growth factor receptor (EGFR) TKI treatment has led to more effective combination therapy and continues to drive development of novel ...

For patients diagnosed with locally advanced or metastatic HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA), the first line of therapy often represents the most meaningful opportunity to ...